The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|October 6, 2015
bottelpack® 430 – compact blow-fill-seal technology
The bottelpack® 430 is a compact blow-fill-seal installation with one mould for the production of ampoules in PE, PP or other resins. It is ideal for small batch sizes.
Advertisement
What is expected from a compact and flexible laboratory BFS machine? On the one hand, there was the requirement to build a compact machine with a minimal mould size to keep the costs for trials and stability tests, etc. with various mould tools low. On the other hand, such a machine should utilize the advantages provided by the rotation machine technology (continuous parison, little plastic waste) of the popular bottelpack® 460/461 models. The result of this mix is the bp430 – a combined shuttle and rotation machine. The basic principle of the rotation machine technology with a continuous, extruded, uncut parison forms the basis for this machine. The mould follows the continuously extruded parison during the blow-fill-seal process. Once the mould has been opened, it cycles back and is positioned directly above the recently produced ampoule bar to shape the next block. This creates a continuous ampoule strip that is fed into an external punch. The bottelpack® 430 is ideal as a laboratory machine and also for small batch sizes. The filling system features state-of-the-art servo motors, an ergonomic design, easy operation and is also equipped with a dark/white separation design.
Contact Details:
rommelag ag
Website:
E-mail:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement